Telix Appoints David Gill As Non-Executive Director, Plans Transition To Board Chair

Telix announced the appointment of David Gill as a Non-Executive Director (NED), effective May 11, 2026, as part of its broader Board expansion and succession planning efforts. Following his appointment, Mr. Gill is expected to assume the role of Chair, succeeding Dr. Mark Nelson, who will continue to serve on the Board as a Non-Executive Director.

David Gill is a highly experienced life sciences executive with more than 35 years of leadership across commercial and clinical-stage biopharmaceutical companies, including those in the radiopharmaceutical and medical device sectors. He currently serves on several boards, including Evolus, Inc., Allucent LLC, Bridge to Life Ltd, RapidPulse Inc., and huMannity Medtec. He was previously a board member at organizations such as Y-mAbs Therapeutics, Inc., Strongbridge Biopharma plc, Alpha Source Inc, Healthtronics, Inc., and Perimetrics, LLC.

Mr. Gill has extensive expertise in capital markets, governance, business scaling, and corporate turnaround strategies. Over the course of his career, he has served as Chief Financial Officer or President at several publicly traded companies, including EndoChoice Holdings, Inc., formerly listed on the NYSE under the symbol GI and later acquired by Boston Scientific; INC Research, previously NASDAQ: INCR and now part of Syneos Health; and CTI Molecular Imaging, once traded on NASDAQ under CTMI before being acquired by Siemens. He holds a Bachelor of Science in Accounting from Wake Forest University and an MBA from Emory University.

Commenting on the appointment, Telix Interim Chair Mark Nelson said that the company is pleased to welcome David Gill to the Board. He noted that Gill’s strong financial background and deep understanding of U.S. capital markets will be highly valuable as Telix continues to grow. Nelson added that the company intends to further strengthen the Board with additional appointments that support Telix’s growth strategy and governance needs as a dual-listed company.